Skip to main content
. 2007 Jun;3(2):291–299. doi: 10.2147/tcrm.2007.3.2.291

Figure 3.

Figure 3

Dose-dependent change in LIC with deferasirox treatment [▪ Deferasirox; □ DFO]. Copyright © 2006. Reprinted with permission from Cappellini MD, Cohen A, Piga A, et al. 2006. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107:3455–62.